Perampanel

Generic Name: Perampanel

Brand Names: Fycompa

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₅N_₃O

CAS Number: 380917-97-5

Unique Ingredient Identifier: H821664NPK

Background: Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behaviora...

Indication: Perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in epileptic patients four years of age and older. It is also indicated as an adjunct in the treatment of primary generalized tonic-clonic seizures in epileptic patients aged 12 years and older.

Associated Conditions: Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy

Phase 4

Completed

Conditions: Electroencephalography

Interventions: Drug: Perampanel

First Posted Date: 2016-09-14

Last Posted Date: 2021-09-29

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 30

Registration Number: NCT02900755

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)

Completed

Conditions: Refractory Epilepsy

Interventions: Drug: Perampanel

First Posted Date: 2016-08-23

Last Posted Date: 2016-08-24

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 110

Registration Number: NCT02876289

Locations: 🇫🇷
Hôpital neurologique, Lyon, France

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Phase 3

Completed

Conditions: Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Interventions: Drug: Perampanel

First Posted Date: 2016-07-29

Last Posted Date: 2022-10-28

Lead Sponsor: Eisai Inc.

Target Recruit Count: 180

Registration Number: NCT02849626

Locations: 🇯🇵
Eisai Trial Site #1, Yokohama-shi, Japan
🇰🇷
Facility #3, Seoul, Korea, Republic of
🇪🇸
Facility #2, Barcelona, Spain

and more 1 locations

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Phase 3

Terminated

Conditions: Lennox-Gastaut Syndrome (LGS)

Interventions: Drug: Placebo
Drug: Perampanel

First Posted Date: 2016-07-15

Last Posted Date: 2022-03-09

Lead Sponsor: Eisai Inc.

Target Recruit Count: 101

Registration Number: NCT02834793

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇮🇳
Synexus Affiliate - Mallikatta Neuro Center, Mangalore, Karnataka, India
🇦🇺
Royal Brisbane & Women's Hospital, Brisbane, Australia

and more 62 locations

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Phase 4

Terminated

Conditions: Epilepsy

Interventions: Drug: perampanel

First Posted Date: 2016-04-04

Last Posted Date: 2017-08-29

Lead Sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC

Target Recruit Count: 8

Registration Number: NCT02727101

Locations: 🇺🇸
MidAtlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Perampanel

First Posted Date: 2016-04-01

Last Posted Date: 2020-02-05

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 106

Registration Number: NCT02726074

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

Phase 2

Conditions: Essential Tremor

Interventions: Drug: Placebo
Drug: Perampanel

First Posted Date: 2016-01-29

Last Posted Date: 2016-09-12

Lead Sponsor: VA Greater Los Angeles Healthcare System

Target Recruit Count: 16

Registration Number: NCT02668146

Locations: 🇺🇸
VA Greater Los Angeles, Los Angeles, California, United States

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Perampanel

First Posted Date: 2015-04-28

Last Posted Date: 2018-07-02

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT02427607

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Phase 4

Completed

Conditions: Brain Tumor, Primary

Interventions: Drug: Perampanel

First Posted Date: 2015-02-16

Last Posted Date: 2018-04-27

Lead Sponsor: Duke University

Target Recruit Count: 9

Registration Number: NCT02363933

Locations: 🇺🇸
The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States

An Extended Access Program (EAP) for Perampanel

Conditions: Primary Generalized Tonic-Clonic or Partial Onset Seizures
Lennox Gastaut Syndrome

First Posted Date: 2014-12-04

Last Posted Date: 2024-06-27

Lead Sponsor: Eisai Inc.

Registration Number: NCT02307578

Locations: 🇪🇪
Tartu University Hospital, Tartu, Estonia
🇧🇪
Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium
🇧🇪
Centre Neurologique William Lennox, Ottignies, Belgium

and more 24 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy